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1191Major randomized studies have substantiated the beneﬁcial
effects of cardiac resynchronization therapy (CRT) in heart
failure (HF) patients with depressed left ventricular ejec-
tion fraction and intraventricular conduction disturbances
who are in sinus rhythm (1–4). Patients with left bundle
branch block (LBBB) have been shown to derive a more
pronounced beneﬁt from CRT than non-LBBB patients
(5,6). Atrial tachyarrhythmias (AT) are the most common
arrhythmias in HF patients (7). However, guidelines on
device implantation have only recently included a class IIa-
IIb recommendation for patients in atrial ﬁbrillation (7,8),
although this recommendation does not distinguish bet-
ween permanent or paroxysmal atrial ﬁbrillation.See page 1198
IAT = intermittent atrial
tachyarrhythmias
ICD = implantable
cardioverter-deﬁbrillator
LAV = left atrial volume
LBBB = left bundle branch
block
LVEF = left ventricular
ejection fractionIn recent years it has been questioned whether patients
with AT gain the same beneﬁt from CRT as patients in
sinus rhythm. However, relevant studies on the subject
have primarily included patients with permanent atrial
ﬁbrillation and showed attenuated effect of CRT in this
study group (9–12). Gasparini et al. (13) and others (10,14)
have suggested that permanent or persistent atrial ﬁbrillation
reduces effective biventricular (BIV) pacing capture, result-
ing in diminished response to CRT, and that atrioventric-
ular nodal ablation may improve survival and response to
CRT (9,12,13,15,16).
Every day clinicians are faced with patients who other-
wise fulﬁll recommended guideline criteria (7,8,17) for CRT
but who have intermittent atrial tachyarrhythmia (IAT).
This aspect is not considered in present guidelines (7,8,17),
and only limited data reﬂect the efﬁcacy of CRT in patients
with IAT before implantation of the device. Therefore, the
question remains whether patients with IAT who otherwise
meet the recommended guideline criteria for CRT derive
beneﬁt from CRT, or if an implantable cardioverter-deﬁ-
brillator (ICD) would sufﬁce in these patients?
Furthermore, even though it has been shown that CRT
induces reverse remodeling of the left atrium, thus reducing
subsequent risk of AT (18), a substantial number of pati-
ents still have atrial tachyarrhythmia (AT) after CRT
implantation (19,20). To the best of our knowledge, no
study has investigated whether development of AT after
CRT implantation affects the clinical beneﬁt of the device.
Accordingly, the present study was carried out among
1,264 LBBB patients enrolled in the MADIT-CRT
(Multicenter Automatic Deﬁbrillator Implantation Trial
With Cardiac Resynchronization Therapy) study and was
designed to evaluate: 1) the effect of IAT before device
implantation on the clinical beneﬁt of CRT; and 2) thereceived grant support from Boston Scientiﬁc, Medtronic, and the Mirowski Foun-
dation. All other authors have reported they have no relationships relevant to the
contents of this paper to disclose.
Manuscript received August 18, 2013; revised manuscript received October 8, 2013,
accepted October 28, 2013.effect of IAT development after
CRT implantation on the clin-
ical beneﬁt of the device.Methods
The MADIT-CRT study. The
study protocol and primary re-
sults of the MADIT-CRT study
have been published previously
(1,21). Brieﬂy, the study ran-
domized 1,820 patients with left
ventricular ejection fraction30%,
ischemic or nonischemic cardio-
myopathy and intraventricular
conduction delay (QRS interval
130 ms) in a 3:2 fashion for
implantation of a CRT-D or an
ICD device. Patients were
excluded if they were in New
York Heart Association func-
tional class III or IV, had a pre-
existing indication for ICD/
CRT-D/pacemaker implantation, had experienced a myocar-
dial infarction within 90 days before enrollment, had atrial
ﬁbrillation within 1 month before enrollment, or presented
with a rhythm other than sinus rhythm at enrollment. The
trial was conducted in 110 centers in the United States,
Canada, and Europe from December 22, 2004, through June
24, 2009, at which time the study was stopped by recom-
mendation of the safety monitoring board. Extended follow-
up was conducted until September 10, 2010.
After the primary publication of MADIT-CRT, subse-
quent analyses showed that the beneﬁt of CRT in the trial
was restricted to patients with LBBB (5,6). Accordingly, the
present study group comprises 1,264 patients with LBBB
who were enrolled in the trial and received a device.
Device programming and interrogation. Standard,
commercially available Boston Scientiﬁc ICD/CRT-D de-
vices were used and implanted by conventional transvenous
implant procedures. All ICD/CRT-D devices were pro-
grammed according to a pre-speciﬁed study protocol (21),
with a ventricular tachycardia zone set at 180 beats/min
and a ventricular ﬁbrillation zone set at 210 beats/min.
All supraventricular tachycardia discriminators and anti-
tachycardia pacing (ATP) were nominally programmed at
“on” mode. Sensitivity was set at the discretion of the
implanting physician. Patients were seen at scheduled visits
1 month after randomization and thereafter quarterly
throughout the follow-up period. The devices were inter-
rogated at each visit, and all interrogation disks were sent to
an independent central core laboratory where an arrhythmia
adjudication committee adjudicated all arrhythmias and
therapies according to pre-deﬁned deﬁnitions.
Endpoints and deﬁnitions. For the current study, the
primary endpoint consisted of a combined endpoint of
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1192all-cause mortality or nonfatal HF events, whichever came
ﬁrst, as previously deﬁned (1). Reverse remodeling measured
by reduction in left atrial volume within a year was deﬁned
as a secondary endpoint. All primary endpoints were adju-
dicated centrally by an assigned HF and mortality com-
mittee according to pre-speciﬁed criteria. LBBB was deﬁned
as prolonged QRS duration (130 ms), QS or rS in lead V1,
wide R-wave in lead I, aVL, and absence of q-wave and
presence of broad R-wave in lead V5 and V6, as previously
reported (5).
Information on history of IAT was on the basis of medical
history taken at enrollment. In-trial development of IAT
was deﬁned as any inappropriate therapy rendered for AT
before the speciﬁc endpoint of HF or death (HF/death),
whichever came ﬁrst. A blinded arrhythmia adjudication
committee evaluated all documented arrhythmias from
device electrocardiograms and categorized them into pre-
speciﬁed categories. The diagnosis of AT included atrial
ﬁbrillation, atrial ﬂutter, and regular supraventricular
tachycardia.
Echocardiography. According to the pre-speciﬁed protocol
as described in the primary paper (1,21), a 2-dimensional
echocardiographic study was performed at baseline and
during the 1-year follow-up. In the present LBBB study
group of 1,264 patients, paired echocardiograms at baseline
and after 1 year were available for 977 patients. An inde-
pendent echocardiographic core laboratory evaluated each
echocardiography and measured left atrial and ventricular
volumes according to the Simpson’s method of disks in the
apical 4-chamber and 2-chamber views (22).
Biventricular pacing. An independent interrogation core
laboratory evaluated the ﬁnal interrogation disks collected
at the last follow-up. Data on the mean percent of
BIV pacing, deﬁned as left ventricular pacing percent
throughout the follow-up, was acquired. According to results
from previous studies, showing a decreased effect of CRT
with <92% BIV pacing (14), we reported the percent of
patients who received an average BIV pacing 92%, with
or without prior history of IAT or in-trial IAT.
Statistics. The MADIT-CRT trial included 1,281 patients
with LBBB. Of these, we excluded 17 patients who never
received a device, leaving 1,264 LBBB patients for the
analyses. Baseline characteristics between LBBB patients
with or without a history of IAT were compared using
nonparametric Wilcoxon or Kruskal-Wallis tests for con-
tinuous variables and the chi-square test or Fisher exact test
for dichotomous variables. To assess changes in echocar-
diographic parameters from baseline to 1-year follow-up,
within a speciﬁc group, we used paired t tests. Changes
between groups were evaluated using the Wilcoxon rank
sum test. To evaluate echocardiographic reverse remodeling
in patients who had in-trial IAT, patients had to have had
in-trial IAT within the ﬁrst year; otherwise, they were
considered as not having had in-trial IAT. For the endpoint
of HF/death, in-trial IAT was deﬁned as inappropriatetherapy for AT that developed before the endpoint of
HF/death.
The cumulative probability of HF/death was displayed
by the method of Kaplan-Meier. Multivariate Cox interac-
tion models were used to assess the efﬁcacy of CRT-D
versus ICD in LBBB patients with and without history of
IAT and in-trial IAT. We adjusted for relevant variables
found by stepwise selection and best subset, only including
variables that entered the model at p values <0.05. The
following variables were included for the endpoint of HF/
death: glomerular ﬁltration rate 60 ml$min1$1.73 m2,
left atrial volume (LAV) indexed by body surface area
(ml/m2), diabetes mellitus, ischemic cardiomyopathy, prior
all-cause hospital stays, and randomized treatment (CRT-
D:ICD). In 2 different models, the effect of respectively prior
IAT or in-trial IAT in CRT-D versus ICD patients was
evaluated by forcing the interaction term between randomized
treatment (CRT-D or ICD) and respectively prior IAT or in-
trial IAT into the model along with the variables themselves.
Hazard ratios (HRs) with their 95% conﬁdence intervals
(CIs) and 2-sided p values were reported. A 2-tailed
p value <0.05 was considered statistically signiﬁcant.
Interaction p values were computed according to standard
methods. Analyses were performed using SAS statistical
system 9.3 version (SAS Institute, Cary, North Carolina).Results
In the MADIT-CRT study, 1,264 patients presented with
LBBB and were implanted with a device. The ICD and
CRT-D devices were implanted in 507 (40%) and 757
(60%) of the 1,264 patients, respectively. During a mean
follow-up of 3.4  1.1 years, 306 (24.2%) of 1,264 patients
reached the primary endpoint of HF/death.
History of IAT. Information on history of IAT was not
acquired in 23 patients, leaving 1,241 patients for this
analysis, of whom 140 (11.3%) had a history of IAT. Table 1
depicts baseline characteristics for patients with or without
a history of prior IAT. There were substantial differences
between the 2 groups, generally emphasizing that patients
with history of IAT had increased frequency of clinical
risk factors. They were more often male, signiﬁcantly older,
and had more comorbidities (advanced renal disease,
ischemic cardiomyopathy, prior myocardial infarction, past
ventricular arrhythmias, and more prior hospital stays),
compared to patients without a history of IAT. These dif-
ferences also reﬂected signiﬁcant differences in baseline
use of medications (Table 1).
Efﬁcacy of CRT-D in LBBB patients with history of IAT.
In the total study group the 4-year cumulative incidence of
HF/death in patients with a history of IAT was 33% as
compared with 25% among patients without a history of
IAT (Fig. 1). Although multivariate Cox regression models
did not show increased risk of HF/death in patients with a
history of IAT (HR: 1.04 [95% CI: 0.75 to 1.45], p ¼ 0.82).
Figure 1
Risk of HF/Death in LBBB Patients Stratiﬁed by
History of IAT
CRT-D ¼ cardiac resynchronization therapy with deﬁbrillator; HF ¼ heart failure;
IAT ¼ intermittent atrial tachyarrhythmia; ICD ¼ implantable cardioverter-deﬁbril-
lator; LBBB ¼ left bundle branch block.
Table 1
Baseline Characteristics Comparing LBBB Patients
With or Without History of IAT
Clinical Characteristics
No History of IAT
(n ¼ 1,101)
History of IAT
(n ¼ 140)
CRT-D implanted 668 (61) 72 (51)*
Female 355 (32) 27 (19)*
Age at enrollment, yrs 63.7  10.9 67.3  9.7*
Heart rate, beats/min 68.5  10.9 66.8  11.2
Creatinine 1.4, mg/dl 209 (19) 41 (29)*
GFR, ml/min/1.73 m2 70.2  20.2 64.2  18.3*
Systolic blood pressure (mm Hg) 122.7  16.9 122.4  18.4
Diastolic blood pressure (mm Hg) 71.6  10.3 70.7  9.8
Nonischemic NYHA class II 646 (59) 52 (37)*
Worst NYHA functional class >2
(>3 months prior)
102 (10) 29 (22)*
Electrocardiographic characteristics
PR interval, ms 196  32 205  35*
QRS, ms 162.4  19.2 167.8  19.8*
Echocardiography characteristics
at baseline
Left ventricular ejection fraction 28.8  3.4 28.3  3.7
LVEDV index, ml/BSA 126.3  30.0 125.4  31.1
LVESV index, ml/BSA 90.4  24.4 90.4  25.3
LAV index, ml/BSA 46.9  10.0 48.8  10.6*
Medical history
Hospital stays in prior year 467 (43) 85 (61)*
Prior HF hospital stays 408 (38) 68 (49)*
Diabetes mellitus 329 (30) 42 (30)
Hypertension 688 (63) 88 (63)
Prior myocardial infarction 325 (30) 68 (51)*
Past ventricular arrhythmias 58 (5) 20 (15)*
Pharmacotherapy at baseline
Antiarrhythmic add agent 29 (3) 55 (39)*
ACE inhibitor or ARB 1058 (96) 137 (98)
Beta-blocker excluding sotalol 1042 (95) 123 (88)*
Digitalis 305 (28) 40 (29)
Diuretic agent 751 (68) 99 (71)
Statins 685 (62) 103 (77)*
Values are n (%) or mean  SD. *p  0.05.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin-receptor blocker; BSA ¼ body surface
area; CRT-D ¼ cardiac resynchronization therapy with deﬁbrillator; GFR ¼ glomerular ﬁltration rate;
HF ¼ heart failure; LAV ¼ left atrial volume; LVEDV ¼ left ventricular end-diastolic volume; LVESV ¼
left ventricular end-systolic volume; NYHA ¼ New York Heart Association.
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1193CRT was associated with a signiﬁcant reduction in the
rate of HF/death compared with ICD-only therapy among
both patients with a history of IAT (Fig. 2A) and patients
without such a history (Fig. 2B). Consistently, multivariate
analysis showed that the overall beneﬁcial effect of CRT-D
versus ICD on the risk of HF/death was similar in
LBBB patients with or without a history of IAT (HR:
0.50 and 0.46, respectively; p for interaction ¼ 0.79)
(Table 2). This effect was primarily driven by a beneﬁt on HF
events that was seen both in LBBB patients with a history of
IAT (HR: 0.36 [95% CI: 0.18 to 0.75], p ¼ 0.006) and in
LBBB patients without a history of IAT (HR: 0.40 [95% CI:
0.30 to 0.53], p < 0.001; p for interaction ¼ 0.80).
History of IAT and change in left atrial volume. As
shown in Table 1, baseline LAV was signiﬁcantly higher
in LBBB patients with than without a history of IAT.However, both patients with or without a history of IAT
had signiﬁcant reduction in LAV within 1 year (% reduction
14.9  11.3, p < 0.001, and 19.1  13.0, p < 0.001,
respectively). This reduction was signiﬁcant in all 4 subgroups
of ICD and CRT-D with or without history of IAT (p <
0.001 in all 4 groups). As shown in Figure 3, LAVwas reduced
to a signiﬁcantly greater degree in CRT-D compared to
ICD patients both with a history of IAT (% reduction
CRT-D 25.9  10.7 vs. ICD 8.2  6.5, p < 0.001) and
without a history of IAT (% reduction CRT-D 29.9  12.0
versus ICD 10.3  7.6, p < 0.001), afﬁrming that LBBB
patients with a history of IAT also derive a beneﬁt of CRT-D
measured by echocardiographic parameters. Similar results
were found for left ventricular volumes (data not shown).
Development of IAT after device implantation and effect
of CRT-D beneﬁt. The cumulative probability of in-trial
development of IAT with ventricular rate above the ICD
detection criteria and resulting in inappropriate therapy
was 4% at 1 year, 6% at 2 years, 8% at 3 years, and 10% at
4 years, without any difference between CRT-D and ICD
patients (p ¼ 0.67). The LBBB patients who experienced
in-trial IAT had a higher frequency of past ventricular
arrhythmias and a slightly shorter QRS duration at baseline
compared to patients who did not experience in-trial IAT.
No other signiﬁcant difference was seen between the groups
(Online Table).
In the total study group, multivariate analysis showed that
the development of in-trial IAT was associated with an
increased risk of subsequent HF/death (HR: 1.63 [95%
CI: 1.06 to 2.50], p ¼ 0.027). The pattern was similar for
in-trial development of atrial ﬁbrillation/ﬂutter in the over-
all LBBB study group (HR: 2.09 [95% CI: 1.21 to 3.59],
p ¼ 0.008). Multivariate analysis, employing development
of in-trial IAT as a time-dependent covariate, showed that
the implantation of a CRT-D device in LBBB patients,
Figure 2
Risk of HF/Death Comparing CRT-D to ICD in
LBBB Patients With and Without History of IAT
(A) Risk of heart failure (HF)/death comparing cardiac resynchronization therapy
with deﬁbrillator (CRT-D) to implantable cardioverter-deﬁbrillator (ICD) in patients
with left bundle branch block (LBBB) and a history of intermittent atrial tachyar-
rhythmia (IAT). (B) Risk of HF/death comparing CRT-D to ICD in patients with LBBB
without a history of intermittent atrial tachyarrhythmia.
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1194was associated with signiﬁcant reductions in the risk of
HF/death when compared to implantation of an ICD
device, irrespective of in-trial development of IAT (p for
interaction ¼ 0.85) (Table 3, Fig. 4). The main effect was
seen in HF events with equal efﬁcacy of CRT-D in LBBB
patients who had in-trial IAT and patients who did not
(HR: 0.47 and HR: 0.39; p for interaction ¼ 0.67). Similar
results were found for in-trial development of atrial ﬁbril-
lation or ﬂutter (Table 3), suggesting that the development
of atrial ﬁbrillation or ﬂutter after CRT-D implantation did
not attenuate the clinical beneﬁt of the device.Table 2 Effects of History of IAT on HF/Death in Comparing CRT-D t
Number of Events/Patients
Hazard Ratio
CRT-D:ICD
No history of IAT 252/1,101 0.46
History of IAT 45/140 0.50
The table shows that patients beneﬁt from CRT-D independently of prior history of intermittent atrial tach
on history of intermittent atrial tachyarrhythmias. Adjusted for glomerular ﬁltration rate 60 (ml$min1
hospital stay, diabetes, ischemic cardiomyopathy, and the interaction variable between implanted devic
ICD ¼ implantable cardioverter-deﬁbrillator.Reverse remodeling in LBBB patients with or without
development of in-trial IAT within the ﬁrst year. Over-
all, LBBB patients with and without development of in-trial
IAT in the ﬁrst year had signiﬁcant reverse remodeling
of LAV at 1-year follow-up (% reduction 20.4  13.0,
p < 0.001, and 18.6  13.0, p < 0.001, respectively), which
was also highly signiﬁcant in all 4 subgroups of ICD and
CRT-D with and without in-trial development of IAT
(p < 0.01).
As shown in Figure 3, LAV was reduced to a greater
degree in CRT-D patients compared to ICD patients who
had in-trial IAT (% reduction 27.2  12.4 vs. 10.2  8.7,
p < 0.001) and in patients who did not have in-trial IAT (%
reduction 29.6  12.0 vs. 9.9  7.4, p < 0.001), afﬁrming
that patients who had in-trial IAT still derived a beneﬁt of
CRT-D. Interestingly, no signiﬁcant difference was seen in
reverse remodeling between CRT-D patients with or
without in-trial IAT (p ¼ 0.34). Similar results were found
for reductions in left ventricular volumes (data not shown).
Biventricular pacing. Data on the mean percent of BIV
pacing at the end of follow-up was available for 632 of 757
(83.4%) of all CRT-D patients with LBBB. The percent of
patients who received BIV pacing 92% was not different
between patients with prior history of IAT (95.0%) and
patients without prior history of IAT (89.6%; p ¼ 0.13).
This was consistent for patients with in-trial IAT (87.5%)
and patients without in-trial IAT (90.2%; p ¼ 0.43), sug-
gesting that there was an efﬁcient resynchronization effect in
both groups, corresponding to the lack of difference seen in
the effect of CRT-D between the groups.Discussion
In the current study, we show a beneﬁcial effect of CRT-D
when compared to ICD in patients with LBBB and
mild HF, irrespective of both a history of IAT as well as
in-trial development of IAT. The beneﬁt of CRT-D
versus ICD on the endpoint of HF/death in LBBB pa-
tients with a history of IAT persisted even though these
patients presented with more comorbidities, which even
further strengthens these ﬁndings. Furthermore, we have
shown that the development of in-trial IAT or only atrial
ﬁbrillation or ﬂutter after CRT-D implantation did not
attenuate the clinical beneﬁt of the device, and that the BIV
pacing percentage remained high even if patients had a his-
tory of IAT or had in-trial IAT.o ICD Treatment in Patients With LBBB
95% Conﬁdence Interval p Value p Value for Interaction
0.36–0.59 <0.001 0.79
0.27–0.93 0.028
yarrhythmias, and that there is no difference in the beneﬁcial effect of CRT on HF/Death depending
$1.73 m2), left ventricular atrial volume at baseline indexed by body surface area (ml/m2), prior
e and history of IAT.
Figure 3
Left Atrial Reverse Remodeling at 1-Year Follow-Up in
LBBB Patients Comparing CRT to ICD in Patients
With or Without Either History of IAT or Interim
Occurrence of IAT Within the First Year
Light blue ¼ ICD; dark blue bars ¼ CRT-D. LAV ¼ left atrial volume; other
abbreviations as in Figure 1.
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1195We showed signiﬁcant reverse remodeling in CRT-D
patients with a history of IAT and in patients with in-trial
IAT measured by reductions in LAV and left ventricular
volumes. These ﬁndings highlight that LBBB patients
with a history of IAT and/or in-trial IAT derive beneﬁt
of CRT-D versus ICD, not only on the endpoint of
HF/death but also on echocardiographic parameters. This
ﬁnding is in accordance with a previous MADIT-CRT
substudy (18) that showed that resynchronization therapy
induces reduction in LAV, resulting in less AT. Of note,
Gasparini et al. (9) failed to show improvement in echo-
cardiographic remodeling parameters in patients with per-
manent atrial ﬁbrillation. We believe that the nature of
IAT allows the myocardium to gain beneﬁt from the
CRT-D device between episodes of AT that would not be
present in patients with permanent AT. Furthermore, with
the positive remodeling of the left atrium we showed in
this study, it might have other beneﬁcial effects including
shortening the paroxysms, diminishing the frequency of
IAT episodes and possibly delaying the natural course of
IAT into permanent AT. These factors might all contribute
to a long-term beneﬁcial effect on mortality.Table 3 Effects of In-Trial Development of IAT Comparing CRT-D to I
Number of Events/Patients
In-trial development of IAT
No in-trial IAT* 283/1,175
In-trial IAT* 23/89
In-trial development of intermittent atrial ﬁbrillation/ﬂutter
No in-trial intermittent atrial ﬁbrillation/ﬂutter* 292/1,217
In-trial intermittent atrial ﬁbrillation/ﬂutter* 14/47
There is a beneﬁcial effect of CRT-D independently of in-trial intermittent atrial tachyarrhythmias or interm
death depending on the occurrence of in-trial intermittent atrial tachyarrhythmias or intermittent atrial ﬁ
atrial volume at baseline indexed by body surface area (ml/m2), prior hospital stays, diabetes mellitus,
in-trial intermittent atrial ﬁbrillation/ﬂutter.
Abbreviations as in Tables 1 and 2.We cannot eliminate the possibility of physician-initiated
pharmacological therapy and/or ICD programming changes
as a consequence of IAT, which could have contributed to
the overall beneﬁt of the CRT-D device. However, we
believe that these interventions should have occurred equally
in ICD and CRT-D patients, and thus, the potential bene-
ﬁcial effect should thereby not impact the overall results of
this study.
Studies investigating the effect of CRT-D in patients
with permanent atrial ﬁbrillation have shown that the
percent of BIV pacing has an important impact on CRT
efﬁcacy. Some studies have suggested that atrial ﬁbrillation
reduces effective BIV pacing capture, resulting in dimin-
ished response to resynchronization therapy (10,13,14) and
that the percentage of BIV pacing should exceed 92% for
the patient to respond to CRT-D treatment (14,23). In
this study, we found that the BIV pacing percentage was still
high, both in patients with prior IAT and in patients who
experienced in-trial IAT. This may very well be due to the
fact that episodes of IAT only cause short periods of reduced
biventricular pacing capture that would not diminish the
overall efﬁcacy of CRT-D in these patients, which might
explain why we do not ﬁnd an attenuated effect of CRT-D
in patients with IAT.
When analyzing both history of IAT as well as in-trial
development of IAT, we believe that we are able to make
an overall evaluation of the impact of IAT on CRT-D
efﬁcacy. We investigated the effect of IAT on subsequent
CRT-D efﬁcacy in patients who otherwise met the gui-
deline criteria for CRT-D implantation (7,8). Previous
studies have focused on permanent or persistent AT and
showed a reduced effect of CRT-D in these patients
(9–12). RAFT (Resynchronization for Ambulatory Heart
Failure Trial) (10) compared the efﬁcacy of CRT-D versus
ICD in patients with permanent atrial ﬁbrillation <90
beats/min and found no signiﬁcant improvement in HF/
death; however, the results were not statistically different
from those for patients without permanent atrial ﬁbrilla-
tion, who had a signiﬁcant reduction in HF/death. In the
RAFT study, the lack of CRT-D effect in patients with
permanent atrial ﬁbrillation with a ventricular rate <90
beats/min might be explained by a lower mean QRSCD in Patients With LBBB on the Endpoint of HF/Death
Hazard Ratio
CRT-D:ICD 95% Conﬁdence Interval p Value
p Value for
Interaction
0.47 0.37–0.60 <0.001 0.85
0.43 0.19–0.99 0.047
0.48 0.38–0.61 <0.001 0.41
0.30 0.10–0.87 0.027
ittent atrial ﬁbrillation/ﬂutter, and that there is no difference in the beneﬁcial effect of CRT on HF/
brillation/ﬂutter. *Adjusted for glomerular ﬁltration rate 60 (ml$min1$1.73 m2), left ventricular
ischemic cardiomyopathy and the interaction variable between implanted device and in-trial IAT or
Figure 4
Effect of In-Trial IAT on Probability of HF/Death in
Patients With LBBB Comparing CRT-D to ICD
Patients
Abbreviations as in Figure 1.
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1196duration at baseline, the failure to stratify by LBBB QRS
morphology, and lower BIV pacing percentage.
In a recent study by Santini et al. (24), in-trial AT
was associated with an increased risk of HF/death in CRT-D
patients. However, this study included a high number
of patients with permanent AT, and it did not compare
CRT-D to ICD, but rather investigated CRT-D patients
with in-trial AT compared to patients without in-trial
AT. It is not surprising that AT, whether before or after
CRT-D implantation, is associated with worse outcome.
Several large studies on HF populations have previously
shown this (25–27). What is important is to investigate,
whether patients with IAT who otherwise meet the rec-
ommended criteria for CRT-D implantation, derive similar
beneﬁcial effects from a CRT-D device as patients with-
out IAT, or whether an ICD would sufﬁce. Our study
indicates that patients with LBBB and IAT beneﬁt equally
from CRT-D as do patients without IAT.
Study limitations. We used device interrogations of inap-
propriate therapy as a marker for in-trial IAT, since we only
have limited data on mode-switch time in the MADIT-
CRT trial. As a result, only arrhythmias above the detec-
tion limit of 180 beats/min are included, and it is therefore
possible that we are underestimating the actual “real-life”
risk of IAT. Furthermore, given the limited data on mode-
switch, we cannot provide any data on arrhythmia burden,
which is known to inﬂuence CRT-D efﬁcacy. We do not
have information on the number of patients who had per-
manent or persistent AT with a ventricular rate below the
device detection limit. However, we suspect the number is
small, since only 41 of 678 (6%) CRT patients had a mode-
switch time >0.5%, and approximately 90% of the patients,
regardless of history of IAT and in-trial IAT, received BIV
pacing 92%, indicating that merely a limited number of
patients had permanent or persistent AT. The BIV pacing
percentage was, unfortunately, not available in 16.6% ofthe patients, and that might have caused some degree of
selection bias. Finally, although we adjusted for several
possible confounding covariates in the multivariate models,
unmeasured confounding may have affected our results to
some degree.
Conclusions
Our ﬁndings from the MADIT-CRT study group
demonstrate that in patients with mild HF and LBBB, the
overall echocardiographic and clinical beneﬁts of CRT-D
are not attenuated among patients who have a prior history
of IAT or among patients who develop IAT after device
implantation. These ﬁndings further stress the pronounced
beneﬁcial effects of CRT-D for patients with mild HF
symptoms regardless of associated IAT.
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